Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login


FDA approves first monoclonal antibody injection for atopic dermatitis

The US Food and Drug Administration (FDA), which is responsible for evaluating the safety and efficacy of medicines in the United States, has approved the use of dupilumab (Dupixent; Regeneron Pharmaceuticals) to treat adults with atopic dermatitis.

Dupilumab is the first monoclonal antibody to be developed for atopic dermatitis and is anticipated as a revolutionary treatment for patients with severe eczema. It is given as a subcutaneous injection and works by targeting the Th2 pathway to inhibit the inflammatory response that drives atopic dermatitis.

Julie Beitz, director of the Office of Drug Evaluation III in the FDA’s Center for Drug Evaluation and Research, says: “The FDA’s approval of Dupixent demonstrates our commitment to approving new and innovative therapies for patients with skin disease.

“Eczema can cause significant skin irritation and discomfort for patients, so it is important to have a variety of treatment options available to patients, including those patients whose disease is not controlled by topical therapies,” she adds.

The safety and efficacy of dupilumab were established in three placebo-controlled clinical trials involving 2,119 adults with moderate-to-severe atopic dermatitis not adequately controlled by topical medication. After 16 weeks of treatment, participants who received dupilumab achieved a greater response compared to controls, and were defined as having ‘clear’ or ‘almost clear’ skin, as well as a reduction in itching.

Side effects associated with the drug include injection site reactions; cold sores in and around the mouth; and redness, swelling and itching around the eyes.

Dupilumab has been under review for marketing authorisation by the European Medicines Agency (EMA) since December 2016.

However, in March 2017, the UK Medicines and Healthcare products Regulatory Agency, which regulates medicines and medical devices in the UK, issued a positive opinion for dupilumab in atopic dermatitis under the ‘Early access to medicines scheme’, meaning that eligible patients will be able to receive the treatment despite it not yet having a marketing authorisation in the EU.

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2017.20202535

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Injectable Drugs Guide

    Injectable Drugs Guide

    A user friendly, single point of reference for healthcare professionals in the safe and effective administration of injectable medicines.

    £52.00Buy now

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Supplementary images

  • Atopic dermatitis

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.